EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands
Abstract
Authors
H Burghoorn Y. Rodriguez-Guadarrama F. van Hees N Smith R Blissett S Vadgama B Doble P Fassler